Tubize-Fin - Asset Resilience Ratio
Tubize-Fin (TUB) has an Asset Resilience Ratio of 0.05% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how Tubize-Fin's Asset Resilience Ratio has changed over time. Check TUB PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Tubize-Fin's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Tubize-Fin.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €900.00K | 0.05% |
| Total Liquid Assets | €900.00K | 0.05% |
Asset Resilience Insights
- Limited Liquidity: Tubize-Fin maintains only 0.05% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Tubize-Fin Industry Peers by Asset Resilience Ratio
Compare Tubize-Fin's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Genfit S.A.
PA:GNFT |
Biotechnology | 64.01% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 22.98% |
|
Altimmune Inc
NASDAQ:ALT |
Biotechnology | 82.06% |
|
Clarity Pharmaceuticals Ltd
AU:CU6 |
Biotechnology | 73.99% |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670 |
Biotechnology | 9.82% |
Annual Asset Resilience Ratio for Tubize-Fin (2002–2025)
The table below shows the annual Asset Resilience Ratio data for Tubize-Fin.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.05% | €900.00K ≈ $1.05 Million |
€1.93 Billion ≈ $2.26 Billion |
-46.12pp |
| 2021-12-31 | 46.17% | €1.51 Billion ≈ $1.76 Billion |
€3.27 Billion ≈ $3.82 Billion |
+43.14pp |
| 2013-12-31 | 3.03% | €54.65 Million ≈ $63.90 Million |
€1.80 Billion ≈ $2.11 Billion |
+2.43pp |
| 2004-12-31 | 0.60% | €4.30 Million ≈ $5.03 Million |
€715.25 Million ≈ $836.21 Million |
+0.54pp |
| 2003-12-31 | 0.06% | €500.00K ≈ $584.55K |
€791.03 Million ≈ $924.80 Million |
-0.01pp |
| 2002-12-31 | 0.07% | €530.00K ≈ $619.63K |
€748.11 Million ≈ $874.61 Million |
-- |
About Tubize-Fin
Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous system. The company was founded in 1928 and is based in Brussels, Belgium.